Quantcast

Latest Glycosides Stories

2009-10-29 10:45:00

OAK BROOK, Ill., Oct. 29 /PRNewswire/ -- PureCircle (LSE: PURE), the world's leading producer of natural high-intensity sweeteners, including Reb A, is pleased to announce the launch of Revive Supplement Water(TM) in New Zealand by Frucor. It is the country's first low-calorie vitamin-enhanced beverage to feature a pure stevia all-natural sweetener. The Revive Supplement Water is sweetened naturally by PureCircle's high-purity Reb A. PureCircle VP Sales Asia Pacific, Chris Hession, said:...

2009-10-12 06:00:00

OAK BROOK, Ill., Oct 12 /PRNewswire/ -- In recognition of the significant commercial and social development opportunities that stevia cultivation and extraction offer regional development, Paraguay Vende, the economic growth program of the United States Agency for International Development (USAID) in conjunction with the government of Paraguay, have signed a cooperation and mutual investment agreement with global stevia firm, PureCircle, to promote the cultivation of stevia in the south...

2009-09-25 05:09:03

Study points way to precisely targeted cancer treatments UC Irvine researchers have created a new approach that vastly improves the targeting of chemotherapeutic drugs to specific cells and organs. Kenneth Longmuir, associate professor of physiology & biophysics, and Richard Robertson, professor of anatomy & neurobiology, used liposomes, small spheres (less-than 100 nanometer in diameter) of naturally-occurring lipid molecules, as "packages" for the cancer chemotherapeutic agent...

2009-09-10 16:27:00

HORSHAM, Pa., Sept. 10 /PRNewswire/ -- Centocor Ortho Biotech Products, L.P. today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its Supplemental New Drug Application (sNDA) for DOXIL (doxorubicin HCI liposome injection) in combination with docetaxel for the treatment of women with locally advanced and metastatic breast cancer. Centocor Ortho Biotech is evaluating the FDA's letter and will respond to the agency as quickly...

2009-07-15 16:22:00

HORSHAM, Pa., July 15 /PRNewswire/ -- Based on the data presented today, the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended that the combination of DOXIL(R) (doxorubicin HCI liposome injection) and docetaxel did not provide a sufficient benefit-risk profile for the treatment of women with locally advanced or metastatic breast cancer. Women with locally advanced and metastatic breast cancer who have received prior anthracycline treatment...

2009-06-29 08:28:55

High ozone conditions cause a 30% decrease in yield and an increase in the concentration of a group of toxic compounds within oilseed rape plants. Combined with the results of previous studies which have shown a decrease in oil, protein and carbohydrate content of oilseed rape seeds in high ozone, these results (to be presented at the Society for Experimental Biology Annual Main Meeting in Glasgow on 29th June 2009) could signal a significant income loss for farmers and an indirect effect on...

2009-05-28 16:01:00

HORSHAM, Pa., May 28 /PRNewswire/ -- Centocor Ortho Biotech Products, L.P. today announced that data related to several compounds will be presented at the 45th American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Fla., from May 29 to June 2, 2009. The studies were sponsored by Centocor Ortho Biotech Products, L.P. or its research partner, Ortho Biotech Oncology Research and Development, a unit of Johnson & Johnson Pharmaceutical Research & Development, L.L.C. "We...

2009-05-21 15:05:00

PALO ALTO, Calif., May 21 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced today that the results from the randomized clinical study of canfosfamide (TELCYTA(R), TLK286) in combination with pegylated liposomal doxorubicin (PLD) vs. PLD will be presented at the 45th annual meeting of the American Society of Clinical Oncology (ASCO) which will be held from May 29 to June 2 in Orlando, FL. Details of the presentation are as follows: -- Abstract #5552 - General Poster...

2009-05-19 10:00:00

Updated Safety data presented at BIO International Convention in Atlanta ATLANTA, May 19 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) released updated safety data today from its pixantrone phase III 301 EXTEND trial demonstrating the effectiveness of pixantrone in patients with relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) for whom anthracycline-related drugs are typically not to be used due to the increased risk of cardiac failure. As noted...

2009-05-13 23:00:00

FLORHAM PARK, N.J., May 14 /PRNewswire/ -- In the keynote speech given in Shanghai at Stevia World 2009 (May 14-15), the annual conference for producers and food and beverage companies, Dorn Wenninger, Corporate VP Supply Chain with PureCircle, the major Reb A producer, announced today that Reb A is now fully competitive with sugar for global brands with global volume. At the conference, Wenninger shared key success factors in his presentation entitled, "Key Success of Reb A to multinational...


Latest Glycosides Reference Libraries

45_20138aaa34c0aef5a2af87b137102229
2009-04-23 11:07:34

Bittercress (Barbarea vulgaris), also commonly known as Herb Barbara, Rocketcress, Yellow Rocketcress, Winter Rocket, and Wound Rocket, is a European biennial herb. This plant displays a rosette of shiny, dark green leaves at the base and additional pinnately divided leaves on the stem. In the spring, yellow flowers originate in tightly packed terminal groups just above the foliage. Bittercress grows wildly as a weed in many parts of North America. The flowers can be in bloom May...

More Articles (1 articles) »
Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.